Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 76 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CHIX:BAVAC with a GF Score™ of 76/100 and a GF Value™ of kr175.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,158 Biotechnology companies, Bavarian Nordic AS ranks worse than 86355.7% on this metric.
During the past 12 months, Bavarian Nordic AS's average EPS without NRI Growth Rate was 17.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bavarian Nordic AS was 73.20% per year. The lowest was -66.80% per year. And the median was 9.80% per year.
Bavarian Nordic AS (CHIX:BAVAc) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bavarian Nordic AS 3-Year EPS without NRI Growth Rate Related Terms
CHIX:BAVAC vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's 3-Year EPS without NRI Growth Rate falls into.
Bavarian Nordic AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 0.00% mean?
Bavarian Nordic AS (CHIX:BAVAC) has a 3-Year EPS without NRI Growth Rate of 0.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bavarian Nordic AS and its competitors. According to the industry distribution chart, Bavarian Nordic AS ranks #999999 out of 1158 companies in the Biotechnology industry.
Is Bavarian Nordic AS's 3-Year EPS without NRI Growth Rate too high?
Bavarian Nordic AS's current 3-Year EPS without NRI Growth Rate is 0.00%. Based on the distribution chart, Bavarian Nordic AS ranks #999999 out of 1158 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #999999 out of 1158 companies for 3-Year EPS without NRI Growth Rate. This places Bavarian Nordic AS in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,158 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current 3-Year EPS without NRI Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr175.97, compared to a current price of kr216.80 — trading 23.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 0.00%. Bavarian Nordic AS's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current 3-Year EPS without NRI Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr216.80 is trading 23.2% above its estimated GF Value™ of kr175.97.
GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.
Key valuation signals for CHIX:BAVAC:
3-Year EPS without NRI Growth Rate: 0.00%
GF Value™: kr175.97 vs. price of kr216.80 (23.2% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
76GF Score
Get the complete analysis for CHIX:BAVAC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
